Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $11.67B | $107.95 | $122.60 | 13.57% | Buy | 5 | 37.76% | 129.12% | 172.24% | 136.79% | |||
| LQDA | LIQUIDIA CORP | $7.95B | $89.42 | $78.17 | -12.58% | Buy | 6 | 70.75% | 206.63% | 560.72% | 151.62% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $28.92B | $216.12 | $373.53 | 72.83% | Strong Buy | 17 | 23.14% | 32.82% | 186.00% | 45.31% | |||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $1.27B | $7.36 | $10.00 | 35.87% | Buy | 1 | 20.98% | 104.29% | 1,840.67% | 61.09% | |||
| HALO | HALOZYME THERAPEUTICS INC | $10.17B | $85.76 | $88.25 | 2.90% | Strong Buy | 4 | 14.00% | 55.88% | 525.51% | 43.18% | |||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $3.32B | $26.43 | $36.67 | 38.73% | Strong Buy | 6 | 19.96% | 108.00% | 152.51% | 68.86% | |||
| ADMA | ADMA BIOLOGICS INC | $2.25B | $10.06 | $17.50 | 73.96% | Strong Buy | 2 | 15.93% | 22.26% | 83.21% | 49.64% | |||
| ASND | ASCENDIS PHARMA A | $15.52B | $249.85 | $302.70 | 21.15% | Strong Buy | 10 | 35.08% | 9.59% | 263.27% | 64.13% | |||
| KRYS | KRYSTAL BIOTECH INC | $9.55B | $322.69 | $353.00 | 9.39% | Strong Buy | 8 | 24.95% | 16.98% | 63.71% | 57.71% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $5.97B | $76.51 | $91.29 | 19.31% | Strong Buy | 7 | 19.26% | 32.32% | 38.00% | 27.74% | |||
| RPRX | ROYALTY PHARMA PLC | $32.92B | $57.26 | $61.80 | 7.93% | Strong Buy | 5 | 14.95% | 48.38% | 42.19% | 20.83% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.88B | $61.46 | $88.00 | 43.18% | Strong Buy | 15 | 15.06% | 67.74% | 26.32% | 19.03% | |||
| VCEL | VERICEL CORP | $2.29B | $44.75 | $62.67 | 40.04% | Strong Buy | 3 | 14.65% | 42.24% | 23.85% | 17.55% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $6.02B | $300.14 | $344.00 | 14.61% | Strong Buy | 7 | 17.50% | 22.87% | 28.31% | 18.43% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $240.54M | $3.04 | $10.50 | 245.39% | Strong Buy | 2 | 14.12% | 21.45% | 35.21% | 27.26% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $705.48M | $11.88 | $27.00 | 127.27% | Strong Buy | 8 | 19.24% | 15.40% | 77.72% | 55.88% | |||
| EXEL | EXELIXIS INC | $12.93B | $52.20 | $51.80 | -0.77% | Hold | 10 | 10.64% | 11.32% | 66.89% | 49.45% | |||
| TECH | BIO-TECHNE CORP | $11.26B | $71.90 | $67.75 | -5.77% | Hold | 8 | 8.33% | 54.53% | 19.73% | 16.13% | |||
| MDXG | MIMEDX GROUP INC | $609.28M | $4.18 | $7.00 | 67.46% | Strong Buy | 3 | -0.77% | 70.85% | 13.77% | 10.58% | |||
| SPRO | SPERO THERAPEUTICS INC | $73.53M | $1.27 | N/A | N/A | N/A | N/A | -21.95% | 83.29% | N/A | N/A | |||
| TGTX | TG THERAPEUTICS INC | $7.58B | $49.55 | $61.00 | 23.11% | Buy | 3 | 27.25% | 8.54% | 101.32% | 37.33% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $16.66B | $256.65 | $278.63 | 8.56% | Strong Buy | 16 | 5.17% | 24.24% | 43.06% | 18.66% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $122.68B | $484.03 | $557.37 | 15.15% | Strong Buy | 19 | 9.10% | 12.65% | 36.48% | 26.94% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $79.49B | $772.11 | $799.44 | 3.54% | Strong Buy | 18 | 8.27% | 15.23% | 24.05% | 18.28% | |||
| UTHR | UNITED THERAPEUTICS CORP | $130.57B | $532.94 | $648.40 | 21.66% | Strong Buy | 10 | 10.81% | 7.42% | 174.03% | 154.27% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.26B | $38.75 | $42.86 | 10.60% | Hold | 7 | 11.43% | 16.96% | 23.24% | 16.92% | |||
| INCY | INCYTE CORP | $24.00B | $118.38 | $116.81 | -1.32% | Buy | 16 | 4.41% | 7.48% | 12.85% | 10.36% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.